J A Kanis1,2, C Cooper3,4, R Rizzoli5, J-Y Reginster6,7. 1. Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK. w.j.Pontefract@shef.ac.uk. 2. Mary McKillop Health Institute, Australian Catholic University, Melbourne, Australia. w.j.Pontefract@shef.ac.uk. 3. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK. 4. NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK. 5. Service of Bone Diseases, Faculty of Medicine, Geneva University Hospitals, Geneva, Switzerland. 6. Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium. 7. WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, Liège, Belgium.
Abstract
This review, endorsed by the International Osteoporosis Foundation and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, summarizes several failings of the recent guidelines of the American College of Physicians (ACP) on the treatment of low bone density or osteoporosis to prevent fractures. INTRODUCTION: The ACP recently issued guidelines for the treatment of low bone density or osteoporosis to prevent fractures. METHODS: Literature review and critical review of the ACP guidelines. RESULTS: The guideline is lacking in scope due to the endorsement of treatment based on T-scores rather than fracture risk assessment and in failure to adequately consider anabolic therapies. CONCLUSIONS: The ACP guideline appears outdated.
This review, endorsed by the International Osteoporosis Foundation and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, summarizes several failings of the recent guidelines of the American College of Physicians (ACP) on the treatment of low bone density or osteoporosis to prevent fractures. INTRODUCTION: The ACP recently issued guidelines for the treatment of low bone density or osteoporosis to prevent fractures. METHODS: Literature review and critical review of the ACP guidelines. RESULTS: The guideline is lacking in scope due to the endorsement of treatment based on T-scores rather than fracture risk assessment and in failure to adequately consider anabolic therapies. CONCLUSIONS: The ACP guideline appears outdated.
Entities:
Keywords:
Bone mineral density; FRAX; Fracture risk; Intervention thresholds; Treatment guidelines
Authors: John A Kanis; Eugene McCloskey; Helena Johansson; Anders Oden; William D Leslie Journal: Calcif Tissue Int Date: 2011-11-06 Impact factor: 4.333
Authors: J Compston; A Cooper; C Cooper; N Gittoes; C Gregson; N Harvey; S Hope; J A Kanis; E V McCloskey; K E S Poole; D M Reid; P Selby; F Thompson; A Thurston; N Vine Journal: Arch Osteoporos Date: 2017-04-19 Impact factor: 2.617
Authors: Kaleen M Lavin; Paul M Coen; Liliana C Baptista; Margaret B Bell; Devin Drummer; Sara A Harper; Manoel E Lixandrão; Jeremy S McAdam; Samia M O'Bryan; Sofhia Ramos; Lisa M Roberts; Rick B Vega; Bret H Goodpaster; Marcas M Bamman; Thomas W Buford Journal: Compr Physiol Date: 2022-03-09 Impact factor: 8.915
Authors: J A Kanis; N C Harvey; E McCloskey; O Bruyère; N Veronese; M Lorentzon; C Cooper; R Rizzoli; G Adib; N Al-Daghri; C Campusano; M Chandran; B Dawson-Hughes; K Javaid; F Jiwa; H Johansson; J K Lee; E Liu; D Messina; O Mkinsi; D Pinto; D Prieto-Alhambra; K Saag; W Xia; L Zakraoui; J -Y Reginster Journal: Osteoporos Int Date: 2019-11-13 Impact factor: 4.507
Authors: M Hiligsmann; J-Y Reginster; A N A Tosteson; S V Bukata; K G Saag; D T Gold; P Halbout; F Jiwa; E M Lewiecki; D Pinto; J D Adachi; N Al-Daghri; O Bruyère; M Chandran; C Cooper; N C Harvey; T A Einhorn; J A Kanis; D L Kendler; O D Messina; R Rizzoli; L Si; S Silverman Journal: Osteoporos Int Date: 2018-10-31 Impact factor: 4.507
Authors: Nannan Li; Dennis Cornelissen; Stuart Silverman; Daniel Pinto; Lei Si; Ingrid Kremer; Sandrine Bours; Robin de Bot; Annelies Boonen; Silvia Evers; Joop van den Bergh; Jean-Yves Reginster; Mickaël Hiligsmann Journal: Pharmacoeconomics Date: 2020-10-07 Impact factor: 4.981
Authors: Elizabeth M Curtis; Jean-Yves Reginster; Nasser Al-Daghri; Emmanuel Biver; Maria Luisa Brandi; Etienne Cavalier; Peyman Hadji; Philippe Halbout; Nicholas C Harvey; Mickaël Hiligsmann; M Kassim Javaid; John A Kanis; Jean-Marc Kaufman; Olivier Lamy; Radmila Matijevic; Adolfo Diez Perez; Régis Pierre Radermecker; Mário Miguel Rosa; Thierry Thomas; Friederike Thomasius; Mila Vlaskovska; René Rizzoli; Cyrus Cooper Journal: Aging Clin Exp Res Date: 2022-03-24 Impact factor: 4.481